Clinical Trial Update: Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia [Phase 1]

View source ↗

Summary

Phase 1 multiple-dose safety study of the investigational drug RN316 for hypercholesterolemia/dyslipidemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Hypercholesterolemia

Drugs mentioned

• RN316

Snippet

Sponsor: Pfizer | Conditions: Hypercholesterolemia, Dyslipidemia | Phase 1 | Status: WITHDRAWN